

# Contents of *The American Journal of Psychiatry*

June 1995

Volume 152

## Editorial

Clozapine: is another view valid? *Herbert Y. Meltzer* 821

## Images in Neuroscience

Cortex VIII: entorhinal cortex in temporal lobe epilepsy. *Essay by Fu Du, Robert Swarcz and Carol A. Tamminga* 826

## Special Article

Patient response and resource management: another view of clozapine treatment of schizophrenia. *William T. Carpenter, Jr., Robert R. Conley, Robert W. Buchanan, Alan Breier and Carol A. Tamminga* 827

## Regular Articles

Stressful life events, genetic liability, and onset of an episode of major depression in women. *Kenneth S. Kendler, Ronald C. Kessler, Ellen E. Walters, Charles MacLean, Michael C. Neale, Andrew C. Heath and Lindon J. Eaves* 833

Results of the DSM-IV mood disorders field trial. *Martin B. Keller, Daniel N. Klein, Robert M. A. Hirschfeld, James H. Kocsis, James P. McCullough, Ivan Miller, Michael B. First, Charles P. Holzer III, Gabor I. Keitner, Deborah B. Marin and Tracie Shea* 843

Platelet serotonin-2A receptors: a potential biological marker for suicidal behavior. *Ghanshyam N. Pandey, Subhash C. Pandey, Yogesh Dwivedi, Rajiv P. Sharma, Philip G. Janicak and John M. Davis* 850

Predicting the "revolving door" phenomenon among patients with schizophrenic, schizoaffective, and affective disorders. *Thomas W. Hayward, Howard M. Kravitz, Linda S. Grossman, James L. Cavanaugh, Jr., John M. Davjs and Dan A. Lewis* 856

A longitudinal follow-up study of seasonal affective disorder. *Kaoru Sakamoto, Susamu Nakadaira, Koji Kamo, Toshiko Kamo and Kiyohisa Takahashi* 862

Variation in ECT use in the United States. *Richard C. Hermann, Robert A. Dorwart, Claudia W. Hoover and Jeremy Brody* 869

High-resolution SPECT study of regional cerebral blood flow in drug-free and drug-naive schizophrenic patients. *Antonio Vita, Sergio Bressi, Daniela Perani, Giordano Invernizzi, Gian Marco Giobbio, Massimiliano Dieci, Marco Garbarini, Angelo Del Sole and Ferruccio Fazio* 876

Lack of sex differences in the neuropsychological performance of patients with schizophrenia. *Terry E. Goldberg, James M. Gold, E. Fuller Torrey and Daniel R. Weinberger* 883

Diagnostic stability in adolescents followed up 2 years after hospitalization. *Jonathan J. F. Mattanah, Daniel F. Becker, Kenneth N. Levy, William S. Edell and Thomas H. McGlashan* 889

Continuities between psychiatric disorders in adolescents and personality disorders in young adults. *Joseph M. Rey, Allen Morris-Yates, Michelle Singh, Gavin Andrews and Gavin W. Stewart* 895

Correlates of accuracy in the assessment of psychiatric inpatients' risk of violence. *Dale E. McNiel and Renée L. Binder* 901

Correlation of CSF 5-HIAA concentration with sociality and the timing of emigration in free-ranging primates. *P. T. Mehlman, J. D. Higley, I. Faucher, A. A. Lilly, D. M. Taub, J. Vickers, S. J. Suomi and M. Linnoila* 907

## Images in Psychiatry

Santiago Ramón y Cajal, 1852–1934. *Essay by Luis Salvador-Carulla* 914

## Brief Reports

Abnormal frontal lobe phosphorous metabolism in bipolar disorder. *Raymond F. Deicken, George Fein and Michael W. Weiner* 915

The last appointment before suicide: is suicide intent communicated? *Erkki T. Isometsä, Martti E. Heikkinen, Mauri J. Marttunen, Markus M. Henriksson, Hillevi M. Aro and Jouko K. Lönnqvist* 919

Seasonal rhythm of platelet [<sup>3</sup>H]mipramine binding in adolescents who attempted suicide. *Daniel S. Pine, Paul D. Trautman, David Shaffer, Lee Cohen, Mark Davies, Michael Stanley and Bruce Parsons* 923

Retreatment for relapse following desipramine discontinuation in dysthymia. *Richard A. Friedman, Jennifer Mitchell and James H. Kocsis* 926

Double-blind, placebo-controlled trial of methylphenidate in older, depressed, medically ill patients. *Amy E. Wallace, Lial L. Kofoed and Alan N. West* 929

Smaller right ear (left hemisphere) advantage for dichotic fused words in patients with schizophrenia. *Gerard Bruder, Esther Rabinowicz, James Towey, Alan Brown, Charles A. Kaufmann, Xavier Amador, Dolores Malaspina and Jack Gorman* 932

Association of intelligence with severity of posttraumatic stress disorder symptoms in Vietnam combat veterans. *Richard J. McNally and Lisa M. Shin* 936

Symptoms of PTSD following recovery of war dead: 13–15-month follow-up. *James E. McCarroll, Robert J. Ursano and Carol S. Fullerton* 939

# Management of Violence and Aggression in Health Care

Edited by Brian Kidd and Cameron Stark

This is the first book to offer a multidisciplinary approach to the diagnosis and management of violence in the working environment. It brings together expert knowledge from medical, nursing, social work and other professionals.

The book describes theories of aggression and violence, preventive measures for the individual clinician and the organisation, and ways of assuaging violence both practically and with the use of medication. It also discusses the role of the organisation and ethical considerations. The practical approach makes this handbook an invaluable tool to all those potentially exposed to aggressive behaviour in their daily professional activities.



● £12.50 ● 200pp. ● 1995  
● ISBN 0 902241 84 2

Available from bookshops and from the Publications Department, Royal College of Psychiatrists, 17 Belgrave Square, London SW1X 8PG (Tel. 0171-235 2351 extension 146)

## Epilim Oral Prescribing Information

**Presentation** Epilim 200 Enteric Coated and Epilim 500 Enteric Coated: Enteric coated tablets containing 200mg, and 500mg Sodium Valproate Ph.Eur. respectively. Epilim Crushable Tablets containing 100mg Sodium Valproate Ph.Eur. Epilim Syrup and Epilim Liquid (sugar free) both containing 200mg Sodium Valproate Ph.Eur. per 5ml. Epilim Chrono 200, Epilim Chrono 300, and Epilim Chrono 500: Controlled release tablets containing a mixture of Sodium Valproate Ph.Eur. and Valproic Acid Fr.P. equivalent to 200mg, 300mg, and 500mg Sodium Valproate respectively. **Indications** Oral formulations of Epilim are indicated for all types of epilepsy. In women of child bearing age Epilim should be used only in severe cases or in those resistant to other treatment. **Dosage and administration** *Adults*; the dose should be titrated at three day intervals until seizure control is achieved. Initially 600mg a day in divided doses increasing in steps of 200mg to a maximum dose of 2500mg per day. *Children over 20kg*; initially 400mg a day in divided doses increasing in steps to a maximum dose of 35mg/kg/day. *Children under 20kg*; initially 20mg/kg/day - the dose may be increased in steps to a maximum of 40mg/kg/day provided that plasma levels are monitored. Epilim Chrono 500 may be given once or twice daily. All other formulations should be given twice daily. **Combination therapy**; levels of Epilim and co-administered anticonvulsants may be affected and optimum dosage is determined by seizure control. **Contraindications, Warnings, etc.** **Contraindications** Active liver disease, family history of severe liver disease, hypersensitivity to valproate. **Side effects** Impaired hepatic function, particularly in children, occasionally leading to hepatic failure - treatment should be withdrawn in patients who suddenly develop symptoms compatible with hepatic disease such as nausea, anorexia, jaundice or malaise. Hyperammonaemia with or without hepatic dysfunction. Blood dyscrasia - impaired platelet function, thrombocytopenia, occasional leucopenia and red cell hypoplasia. Occasionally increased appetite, weight gain, transient hair loss, behavioural disturbances, alterations to the menstrual cycle and pancreatitis. Symptoms of intoxication include ataxia, tremor, and stupor. **Drug interactions** Epilim has significant interactions with phenytoin, lamotrigine and other anticonvulsants. Epilim may potentiate the effects of neuroleptics, MAOIs and other antidepressants, anticoagulants and salicylates. Cimetidine may inhibit the metabolism of Epilim. Epilim has no effect on the efficacy of oral contraceptives. **Pregnancy** An increased incidence of congenital abnormalities has been demonstrated in offspring born to mothers with epilepsy both untreated and treated, including those treated with sodium valproate. Neural tube defects have been reported in about 1% of offspring of women who have received valproate during the first trimester of pregnancy. Pregnancies should be screened for neural tube defects by estimation of alpha-fetoprotein and ultrasound. Folate supplementation has been shown to reduce the incidence of neural tube defects in the offspring of high risk women. **Legal category** P.O.M. **Further information** Epilim is hygroscopic - tablets should not be removed from their foil until they are used. Epilim Chrono is recommended in cases where plasma valproate levels are being measured on account of its pharmacokinetics. The effective therapeutic range for valproate is 40-100mg/l (278-694 micromol/l). **Product Licence Numbers** Epilim 200 Enteric Coated 11723/0018, Epilim 500 Enteric Coated 11723/0020, Epilim 100mg Crushable Tablets 11723/0017, Epilim Syrup 11723/0025, Epilim Liquid 11723/0024, Epilim Chrono 200 11723/0078, Epilim Chrono 300 11723/0021, Epilim Chrono 500 11723/0079. **NHS Cost** Epilim 200 Enteric Coated 100 tablets £6.42, Epilim 500 Enteric Coated 100 tablets £16.04, Epilim 100mg Crushable Tablets 100 tablets £3.89, Epilim Syrup 300ml £5.89, Epilim Liquid 300ml £5.89, Epilim Chrono 200 100 tablets £7.70, Epilim Chrono 300 100 tablets £11.55, Epilim Chrono 500 100 tablets £19.25. **Address:** Sanofi Winthrop Ltd., One Onslow Street, Guildford, Surrey GU1 4YS. **Telephone:** (01483) 505515 **Fax:** (01483) 35432. Epilim, Epilim Chrono and the Chrono device are registered trade marks. **Date of preparation** April 1995.

## References:

1. Chadwick D., *J. Neurol. Neurosurg. Psychiatry* 1994; **57**: 264-277.
2. Gilham R.A., *Epilepsy Res.*, 1990; **7**: 219-225.



# Give someone with epilepsy a future to look forward to

People with epilepsy have the same aspirations as anybody else. What they need is a treatment which allows them to fulfil their potential.


Whatever the type of epilepsy, Epilim Chrono can help. Effective both in generalized and partial seizures,<sup>1</sup> it is well tolerated (particularly with regard to cognitive function)<sup>2</sup>, and offers patients the convenience of once-daily dosing.\*

It helps people with epilepsy get on with their lives today, and look forward to tomorrow.

A young girl in a white tutu and ballet slippers stands in profile, looking into a large, arched wooden mirror. The mirror reflects a ballerina in a white tutu performing a graceful pose. The scene is set against a soft, light background, suggesting a stage or rehearsal space. The overall mood is one of aspiration and hope.

**\*500mg Tablets**  
**Epilim<sup>®</sup> CHRONO<sup>®</sup>**  
Sodium Valproate Ph. Eur.  
Valproic Acid Fr.P Controlled Release

**Once-daily management  
for all forms of epilepsy**



# LUSTRAL<sup>\*</sup>

sertraline

**Builds a successful recovery  
from depression with anxiety**

Further information is available on request from:  
Richborough<sup>\*</sup> Pharmaceuticals or Invicta<sup>\*</sup> Pharmaceuticals,  
Divisions of Pfizer Limited, Sandwich, Kent.  
Legal Category: POM <sup>\*</sup>Trade Mark  
66214 Dec 94

